Research Paper Volume 14, Issue 4 pp 1836—1847

KCNQ1OT1 polymorphism rs35622507 and methylation status of KCNQ1OT1 promoter influence the drug resistance to L-OHP

class="figure-viewer-img"

Figure 1. Differential expression of KCNQ1OT1, miR-34a and ATG4B mRNA in colon cancer tissue samples with distinct genotypes and methylation levels of KCNQ1OT1 promoters. (A) Increased IC50 by L-OHP treatment in Group A, Group B, Group C and Group D (statistical analysis: one-way ANOVA; * P value < 0.05, F value = 8.43 vs. Group A; ** P value < 0.05, F value = 9.52 vs. Group B; # P value < 0.05 F value = 11.22 vs. Group C). (B) Increased expression of KCNQ1OT1 in Group A, Group B, Group C and Group D (statistical analysis: one-way ANOVA; * P value < 0.05, F value = 10.96 vs. Group A; ** P value < 0.05, F value =6.37 vs. Group B; # P value < 0.05 F value = 9.58 vs. Group C). (C) Decreased expression of miR-34a in Group A, Group B, Group C and Group D (statistical analysis: one-way ANOVA; * P value < 0.05, F value = 5.81 vs. Group A; ** P value < 0.05, F value = 10.99 vs. Group B; # P value < 0.05 F value = 11.95 vs. Group C). (D) Increased expression of ATG4B mRNA in Group A, Group B, Group C and Group D (statistical analysis: one-way ANOVA; * P value < 0.05, F value = 9.74 vs. Group A; ** P value < 0.05, F value = 7.27 vs. Group B; # P value < 0.05 F value = 6.39 vs. Group C).